In a report released today, Michael Matson from Needham maintained a Buy rating on Inogen (INGN - Research Report), with a price target of $36.00. The company's shares opened today at $21.96.According to TipRanks, Matson is an analyst with an average return of -0.9% and a 44.12% success rate. Matson covers the Healthcare sector, focusing on stocks such as Atricure, Medtronic, and NeoGenomics.Currently, the analyst consensus on Inogen is a Moderate Buy with an average price target of $36.00.See the top stocks recommended by analysts >>Based on Inogen's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $103.
https://www.tipranks.com/news/blurbs/inogen-ingn-gets-a-buy-from-needham?utm_source=advfn.com&utm_medium=referral